Through a regulatory-compliant and ethical channel on a named-patient basis, Idis Access Programs enable patients worldwide to be prescribed investigational or approved drugs prior to their commercial launch in the patient’s country.
Since April 2012, Corcept has been offering Korlym in the U.S. as a once-daily oral treatment for hyperglycemia secondary to endogenous Cushing’s syndrome in adult patients with type 2 diabetes or glucose intolerance who have failed surgery or are not candidates for surgery.
“We are pleased to partner with Idis so that physicians outside the United States can prescribe Korlym,” said Corcept Vice President of Commercial Operations Steven Lo. “We are dedicated to meeting the needs of patients worldwide. Our partnership with Idis will help us make sure that every Cushing’s syndrome patient who could benefit from Korlym will have access to the medicine.”
Interested licensed healthcare professionals outside the U.S. who have patients that might benefit from Korlym can contact Idis directly for more information.
For more information, visit www.corcept.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
